GlaxoSmithKline neurology news
GlaxoSmithKline said in a statement on July 22 that senior GSK executives in China "appear to have acted outside of our processes and controls which breaches Chinese law." Earlier this month, the pharma said it was conducting a review of its compliance procedures in China following a July 11 statement from China's Ministry of Public Security that senior GSK executives in China confessed to bribery and tax crimes. The ministry had said it arrested several GSK executives after finding evidence they had bribed government officials, foundations, hospitals and doctors (see BioCentury, July 15).
Additionally, according to a July 23 article in The New York Times, an internal 2011 GSK audit found that GSK researchers did not report data from some preclinical trials of ozanezumab prior to starting human trials and that workers at the Shanghai R&D center did not properly monitor trials and paid hospitals in ways that could be seen as bribery. Ozanezumab ( 1223249), a humanized mAb against reticulon 4 ( RTN4; NOGO-A; NOGO; NOGO-B), is in Phase II testing for amyotrophic lateral sclerosis (ALS). GSK said in a statement that the 2011 report "presented a number of recommendations which were implemented" and that a follow-up audit a year later "gave the organization in China the highest possible rating." ...